Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Institute for Experimental Cardiology, Heidelberg University Hospital, Heidelberg, Germany.
Am J Physiol Heart Circ Physiol. 2021 May 1;320(5):H2066-H2079. doi: 10.1152/ajpheart.00036.2021. Epub 2021 Mar 26.
Heart failure (HF) is a multifactorial syndrome that remains a leading cause of worldwide morbidity. Despite its high prevalence, only half of patients with HF respond to guideline-directed medical management, prompting therapeutic efforts to confront the molecular underpinnings of its heterogeneity. In the current study, we examined epigenetics as a yet unexplored source of heterogeneity among patients with end-stage HF. Specifically, a multicohort-based study was designed to quantify cardiac genome-wide cytosine-p-guanine (CpG) methylation of cardiac biopsies from male patients undergoing left ventricular assist device (LVAD) implantation. In both pilot ( = 11) and testing ( = 31) cohorts, unsupervised multidimensional scaling of genome-wide myocardial DNA methylation exhibited a bimodal distribution of CpG methylation found largely to occur in the promoter regions of metabolic genes. Among the available patient attributes, only categorical self-identified patient race could delineate this methylation signature, with African American (AA) and Caucasian American (CA) samples clustering separately. Because race is a social construct, and thus a poor proxy of human physiology, extensive review of medical records was conducted, but ultimately failed to identify covariates of race at the time of LVAD surgery. By contrast, retrospective analysis exposed a higher all-cause mortality among AA (56.3%) relative to CA (16.7%) patients at 2 yr following LVAD placement ( = 0.03). Geocoding-based approximation of patient demographics uncovered disparities in income levels among AA relative to CA patients. Although additional studies are needed, the current analysis implicates cardiac DNA methylation as a previously unrecognized indicator of socioeconomic disparity in human heart failure outcomes. A bimodal signature of cardiac DNA methylation in heart failure corresponds with racial differences in all-cause mortality following mechanical circulatory support. Racial differences in promoter methylation disproportionately affect metabolic signaling pathways. Socioeconomic factors are associated with racial differences in the cardiac methylome among men with end-stage heart failure.
心力衰竭(HF)是一种多因素综合征,仍然是全球发病率的主要原因。尽管 HF 的患病率很高,但只有一半的 HF 患者对指南指导的医学管理有反应,这促使治疗努力应对其异质性的分子基础。在目前的研究中,我们研究了表观遗传学作为终末期 HF 患者异质性的一个尚未探索的来源。具体来说,设计了一项多队列研究来定量分析接受左心室辅助装置(LVAD)植入的男性患者心脏活检的心脏全基因组胞嘧啶-鸟嘌呤(CpG)甲基化。在试点(=11)和测试(=31)队列中,全基因组心肌 DNA 甲基化的无监督多维尺度分析显示 CpG 甲基化呈双峰分布,主要发生在代谢基因的启动子区域。在可用的患者属性中,只有分类自我识别的患者种族可以描绘这种甲基化特征,非洲裔美国(AA)和白种美国(CA)样本分别聚类。由于种族是一种社会建构,因此是人类生理学的一个糟糕的代表,因此进行了广泛的病历审查,但最终未能在 LVAD 手术时确定种族的协变量。相比之下,回顾性分析暴露了 AA(56.3%)患者的全因死亡率明显高于 CA(16.7%)患者在 LVAD 放置后 2 年(=0.03)。基于地理编码的患者人口统计学近似值揭示了 AA 患者相对 CA 患者的收入水平存在差异。尽管还需要进一步的研究,但目前的分析表明心脏 DNA 甲基化是人类心力衰竭结局中社会经济差异的一个以前未被认识到的指标。心力衰竭中心脏 DNA 甲基化的双峰特征与机械循环支持后种族之间的全因死亡率差异相对应。启动子甲基化的种族差异不成比例地影响代谢信号通路。社会经济因素与终末期心力衰竭男性心脏甲基组中种族差异有关。